|
New SARS-CoV-2 papain-like protease inhibitor compounds are potent antiviral drug candidates
Binding site of the target papain-like protease of the SARS-CoV-2 virus targeted by these inhibitors. Figure reproduced from inventors’ related paper in Science describing unrelated compounds (link).
Invention Summary:
The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts...
Published: 8/8/2025
|
Inventor(s): Jun Wang, Bin Tan, Prakash Jadhav
Keywords(s):
Category(s): Technology Classifications > COVID-19, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
|
|
Telaprevir-derived Enterovirus D68 2A protease inhibitors are antiviral drug candidates
Published data for lead compounds, the telaprevir-derived 2Apro inhibitor Jun11762 and others, demonstrate substantial improvement over Telaprevir in plaque assay. See link to paper below.
Invention Summary:
The genus Enterovirus of Picornaviridae contains many significant pathogens related to human and mammalian diseases. Enterovirus D68...
Published: 7/31/2025
|
Inventor(s): Jun Wang, Bin Tan, Prakash Jadhav, Kan Li
Keywords(s): Antiviral, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
|
|
Fumaramide SARS-CoV-2 papain-like protease inhibitors are antiviral drug candidates
Published data for lead compound, the fumaramide PLpro inhibitor Jun13728, demonstrate potent inhibition of SARS-CoV2 variants including nirmatrelvir-resistant mutant (light blue). Link to paper below.
Invention Summary:
The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for...
Published: 7/31/2025
|
Inventor(s): Jun Wang, Bin Tan, Prakash Jadhav, Ahmadullah Ansari, Francesc Ruiz Figueras, Edward Arnold
Keywords(s):
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Quinoline-derived SARS-CoV-2 papain-like protease inhibitors are oral antiviral drug candidates
A lead compound, the quinoline-derived PLpro inhibitor Jun13296, demonstrates substantial protection against SARS-CoV-2 infection and adverse clinical outcomes.
Invention Summary:
The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for research to support pandemic preparedness...
Published: 7/31/2025
|
Inventor(s): Jun Wang, Prakash Jadhav, Bin Tan, Haozhou Tan
Keywords(s): Antiviral
Category(s): Technology Classifications > COVID-19, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
|
|
SARS-COV-2 papain-like protease inhibitors as antivirals
Novel compounds and their use as an inhibitor for SARS-CoV-2.
Invention Summary:
Two oral SARS-CoV-2 antivirals are available, molnupiravir and Paxlovid. However, the limited efficacy, drug-drug interaction, and drug resistance are main challenges facing these two drugs. Additional oral antivirals with novel mechanisms of actions are clearly needed....
Published: 7/9/2025
|
Inventor(s): Jun Wang, Edward Arnold, Francesc Ruiz Figueras, Prakash Jadhav, Bin Tan, Ahmadullah Ansari, Ashima Chopra
Keywords(s): Antiviral, Small molecules
Category(s): Technology Classifications > COVID-19, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences
|
